Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1984 2
1985 2
1986 2
1990 1
1992 7
1993 3
1994 1
1995 4
1996 4
1997 1
1998 4
1999 3
2000 2
2001 4
2002 1
2003 5
2005 3
2006 7
2007 6
2008 7
2009 7
2010 7
2011 7
2012 5
2013 8
2014 7
2015 7
2016 7
2017 3
2018 1
2019 1
2020 4
2021 4
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

123 results
Results by year
Filters applied: . Clear all
Page 1
TP53 and ovarian cancer.
Schuijer M, Berns EM. Schuijer M, et al. Among authors: berns em. Hum Mutat. 2003 Mar;21(3):285-91. doi: 10.1002/humu.10181. Hum Mutat. 2003. PMID: 12619114 Free article. Review.
The changing view of high-grade serous ovarian cancer.
Berns EM, Bowtell DD. Berns EM, et al. Cancer Res. 2012 Jun 1;72(11):2701-4. doi: 10.1158/0008-5472.CAN-11-3911. Epub 2012 May 16. Cancer Res. 2012. PMID: 22593197 Free article. Review.
MicroRNAs in ovarian cancer biology and therapy resistance.
van Jaarsveld MT, Helleman J, Berns EM, Wiemer EA. van Jaarsveld MT, et al. Among authors: berns em. Int J Biochem Cell Biol. 2010 Aug;42(8):1282-90. doi: 10.1016/j.biocel.2010.01.014. Epub 2010 Jan 18. Int J Biochem Cell Biol. 2010. PMID: 20083225 Review.
LH receptor gene mutations and polymorphisms: an overview.
Piersma D, Verhoef-Post M, Berns EM, Themmen AP. Piersma D, et al. Among authors: berns em. Mol Cell Endocrinol. 2007 Jan 2;260-262:282-6. doi: 10.1016/j.mce.2005.11.048. Epub 2006 Oct 9. Mol Cell Endocrinol. 2007. PMID: 17030087 Review. No abstract available.
Tamoxifen resistance in breast cancer: elucidating mechanisms.
Dorssers LC, Van der Flier S, Brinkman A, van Agthoven T, Veldscholte J, Berns EM, Klijn JG, Beex LV, Foekens JA. Dorssers LC, et al. Among authors: berns em. Drugs. 2001;61(12):1721-33. doi: 10.2165/00003495-200161120-00004. Drugs. 2001. PMID: 11693462 Review.
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.
Sanij E, Hannan KM, Xuan J, Yan S, Ahern JE, Trigos AS, Brajanovski N, Son J, Chan KT, Kondrashova O, Lieschke E, Wakefield MJ, Frank D, Ellis S, Cullinane C, Kang J, Poortinga G, Nag P, Deans AJ, Khanna KK, Mileshkin L, McArthur GA, Soong J, Berns EMJJ, Hannan RD, Scott CL, Sheppard KE, Pearson RB. Sanij E, et al. Among authors: berns emjj. Nat Commun. 2020 May 26;11(1):2641. doi: 10.1038/s41467-020-16393-4. Nat Commun. 2020. PMID: 32457376 Free PMC article.
123 results